Neurology · AntiepilepticPipeline Updatecompetitivemid-term

FDA Submission Update for Topiramate by Aiping Pharm Inc.

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/18/2026, 12:32:16 PM

Assessment confidence: 70% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The submission of ANDA078499 for Topiramate by Aiping Pharm Inc. signifies an impending increase in competition within the antiepileptic market. This could lead to shifts in pricing strategies and market dynamics that pharma companies must proactively manage. Regulatory context from FDA (FDA AP — TOPIRAMATE (SUPPL)) supports the near-term read. Assessment grounded in 26 ranked evidence items (13 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies for Topiramate. The strongest clinical anchor is A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov), sponsor/company relevance (astrazeneca). In Neurology · Antiepileptic, 8 regulatory and 4 competitive items passed relevance filtering for Topiramate.

Competitive Pressure

The most relevant competitive pressure comes from ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis (Humanexa Signals) — entity match (neurology). Secondary pressure from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study. This submission indicates Aiping Pharm Inc.'s intent to enter the market for Topiramate, potentially increasing competition in the antiepileptic drug space.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — TOPIRAMATE (SUPPL) (FDA). Entity match (topiramate); Regulatory pathway relevance (nda). The submission has a standard review priority, indicating that while it is being evaluated, it is not expected to face significant regulatory hurdles.

Key Opportunities

Increased competition may pressure pricing and market share for existing Topiramate products, impacting revenue streams for current manufacturers.
Upside for Topiramate may improve if A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Topiramate may improve if Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities. (PubMed) delivers favorable follow-through.
Upside for Topiramate may improve if Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants (ClinicalTrials.gov) delivers favorable follow-through.
Portfolio teams should assess the potential impact of this submission on market dynamics and pricing strategies for Topiramate.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress of ANDA078499 and any subsequent approvals or market entries by Aiping Pharm Inc.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — TOPIRAMATE (ORIG)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (SUPPL)
FDAhigh relevance
Entity match (topiramate); Regulatory pathway relevance (nda)
FDA document
View source

A Study to Investigate the Effect of AZD6234, AZD9550, and Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Part
ClinicalTrials.govhigh relevance
Sponsor/company relevance (AstraZeneca)
FDA document
View source
Multimorbidity and Polypharmacy in People With HIV vs.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Trial to Evaluate the Impact of Various Pragmatic Interventions to Increase Mammography Uptake Among Defaulted Repeat Screeners in Singapore
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Pre-incisional Infiltration With Ropivacaine Plus Triamcinolone for Relieving Postoperative Pain After Thoracoscopic Surgery
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of LAI MMV055 Alone and in Combination With MMV371 in Healthy Participants
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Subjects
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of Intravenous Injection of Erythropoietin on Hepcidin Pharmacokinetics in Healthy Volunteers
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

ACADIA Pharmaceuticals initiates ACP-204 trials for Alzheimer's Disease Psychosis
Humanexa Signalshigh relevance
Entity match (neurology)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Entity match (neurology)
Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Entity match (neurology)
Phase 3 Trial of Orelabrutinib in Secondary Progressive MS Underway
Humanexa Signalshigh relevance
Entity match (neurology)

Lysosome-directed targeted protein degradation technologies for overcoming cancer drug resistance: mechanisms, design principles, and therapeutic opportunities.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Gut microbial markers of immunotherapy response in melanoma: a cross-cohort analysis including the first Russian dataset.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Potential implications of increased utilization of oral nirmatrelvir/ritonavir in outpatient care for COVID-19: modeled findings from the Spanish National Health System perspective.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Comparison of Transumbilical Single‑Port and Multi‑Port Laparoscopic Myomectomy in Patients with Uterine Fibroids: Effects on Stress Response, Immune Function, and Incision Cosmetic Outcomes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lavandula angustifolia as a dual pharmacological system: from essential oil to polyphenol-rich biomass.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Immune response to rotavirus vaccines in low- and middle-income countries: Challenges and perspectives.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Topiramate
Epilepsy
Neurology

Commercial impact

medium

Increased competition may pressure pricing and market share for existing Topiramate products, impacting revenue streams for current manufacturers.

Regulatory impact

low

The submission has a standard review priority, indicating that while it is being evaluated, it is not expected to face significant regulatory hurdles.

What to watch

Monitor the review progress of ANDA078499 and any subsequent approvals or market entries by Aiping Pharm Inc.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.